Rifampicin Resistance Pattern of Mycobacterium tuberculosis Infection in Tertiary Care Hospital Settings

This study investigates antimicrobial resistance (AMR) patterns in Mycobacterium tuberculosis (MTB) infections in tertiary care hospitals. A retrospective analysis of 138 clinical samples from patients with suspected MTB infections from November 2022 to April 2023 revealed marked resistance to Rifampicin (RIF), with 14 samples showing positive results (10.14%). This raises concerns about the effectiveness of standard tuberculosis treatment regimens in the country. The study emphasizes the need for continuous surveillance, diagnostic strategies, and effective treatment protocols to combat AMR in MTB infections. Understanding the AMR landscape is crucial for optimizing therapeutic interventions and reducing the global burden of tuberculosis.